John A. Josey

4.4k total citations · 1 hit paper
28 papers, 2.3k citations indexed

About

John A. Josey is a scholar working on Molecular Biology, Organic Chemistry and Cancer Research. According to data from OpenAlex, John A. Josey has authored 28 papers receiving a total of 2.3k indexed citations (citations by other indexed papers that have themselves been cited), including 18 papers in Molecular Biology, 13 papers in Organic Chemistry and 6 papers in Cancer Research. Recurrent topics in John A. Josey's work include Chemical Synthesis and Analysis (9 papers), Cancer, Hypoxia, and Metabolism (5 papers) and DNA and Nucleic Acid Chemistry (5 papers). John A. Josey is often cited by papers focused on Chemical Synthesis and Analysis (9 papers), Cancer, Hypoxia, and Metabolism (5 papers) and DNA and Nucleic Acid Chemistry (5 papers). John A. Josey collaborates with scholars based in United States, Japan and Sweden. John A. Josey's co-authors include James M. Veal, Laurie Betts, Steven R. Jordan, Eli M. Wallace, Stephen F. Martin, C. Fred Hassman, Stephen A. Thomson, Daniel J. Ricca, Rodolfo Cadilla and Stewart A. Noble and has published in prestigious journals such as Nature, Science and Journal of the American Chemical Society.

In The Last Decade

John A. Josey

28 papers receiving 2.2k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

On-target efficacy of a HIF-2α antagonist in preclinical kidney cancer models

2016 336 citations Hyejin Cho, Xinlin Du et al. Nature profile →

Peers

Countries citing papers authored by John A. Josey

Since Specialization

Citations

This map shows the geographic impact of John A. Josey's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by John A. Josey with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites John A. Josey more than expected).

Fields of papers citing papers by John A. Josey

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by John A. Josey. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by John A. Josey. The network helps show where John A. Josey may publish in the future.

Co-authorship network of co-authors of John A. Josey

This figure shows the co-authorship network connecting the top 25 collaborators of John A. Josey. A scholar is included among the top collaborators of John A. Josey based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with John A. Josey. John A. Josey is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	3-[(1S,2S,3R)-2,3-Difluoro-1-hydroxy-7-methylsulfonylindan-4-yl]oxy-5-fluorobenzonitrile (PT2977), a Hypoxia-Inducible Factor 2α (HIF-2α) Inhibitor for the Treatment of Clear Cell Renal Cell Carcinoma 2019 ·Journal of Medicinal Chemistry ·Rui Xu, Keshi Wang, James P. Rizzi, (unknown), Jonas Grina, Stephen T. Schlachter, Bin Wang, Paul M. Wehn, Hanbiao Yang, Darryl D. Dixon, Robert Czerwiński, Xinlin Du, (unknown), Guangzhou Han, Huiling Tan, Tai‐Tong Wong, Shanhai Xie, John A. Josey, Eli M. Wallace	156
2	Phase I Dose-Escalation Trial of PT2385, a First-in-Class Hypoxia-Inducible Factor-2α Antagonist in Patients With Previously Treated Advanced Clear Cell Renal Cell Carcinoma 2017 ·Journal of Clinical Oncology ·Kevin D. Courtney, Jeffrey R. Infante, Elaine T. Lam, Robert A. Figlin, Brian I. Rini, James Brugarolas, Naseem J. Zojwalla, Ann M. Lowe, Keshi Wang, Eli M. Wallace, John A. Josey, Toni K. Choueiri	296
3	On-target efficacy of a HIF-2α antagonist in preclinical kidney cancer models breakdown → 2016 ·Nature ·Hyejin Cho, Xinlin Du, James P. Rizzi, Ella Liberzon, Abhishek A. Chakraborty, Wenhua Gao, Ingrid Carvo, Sabina Signoretti, Richard K. Bruick, John A. Josey, Eli M. Wallace, William G. Kaelin	336
4	A phase I dose escalation trial of PT2385, a first-in-class oral HIF-2a inhibitor, in patients with advanced clear cell renal cell carcinoma. 2016 ·Journal of Clinical Oncology ·Kevin D. Courtney, Jeffrey R. Infante, Elaine T. Lam, Robert A. Figlin, Brian I. Rini, James Brugarolas, Naseem J. Zojwalla, Keshi Wang, Eli Wallace, John A. Josey, Toni K. Choueiri	5
5	Abstract 4022: PT2385, a novel HIF-2α antagonist, combines with checkpoint inhibitor antibodies to inhibit tumor growth in preclinical models by modulating myeloid cells and enhancing T cell infiltration 2016 ·Cancer Research ·Guangzhou Han, Christina Stevens, Zhaodan Cao, Shanhai Xie, Melissa A. Maddie, Barry S. Goggin, Eli Wallace, John A. Josey, Tai W. Wong	5
6	Non-nucleoside inhibitors of HCV NS5B polymerase. Part 1: Synthetic and computational exploration of the binding modes of benzothiadiazine and 1,4-benzothiazine HCV NS5b polymerase inhibitors 2009 ·Bioorganic & Medicinal Chemistry Letters ·R. Hendricks, Jay B. Fell, James F. Blake, John P. Fischer, John Robinson, (unknown), Peter J. Stengel, (unknown), Vincent Lévêque, Sophie Le Pogam, Sonal Rajyaguru, Isabel Nájera, John A. Josey, Jason Harris, Steven Swallow	27
7	Synthesis and SAR of 2-phenyl-1-sulfonylaminocyclopropane carboxylates as ADAMTS-5 (Aggrecanase-2) inhibitors 2009 ·Bioorganic & Medicinal Chemistry Letters ·Makoto Shiozaki, Hiroto Imai, Katsuya Maeda, Tomoya Miura, Katsutaka Yasue, (unknown), Masahiro Yokota, (unknown), Julia Haas, Andrew M. Fryer, Ellen R. Laird, (unknown), Steven W. Andrews, John A. Josey, (unknown), Yuichi Shinozaki, (unknown), Takashi Inaba	16
8	3-Hydroxyisoquinolines as inhibitors of HCV NS5b RNA-dependent RNA polymerase 2008 ·Bioorganic & Medicinal Chemistry Letters ·R. Hendricks, (unknown), James F. Blake, Jay B. Fell, John P. Fischer, Peter J. Stengel, Vincent Lévêque, (unknown), Sonal Rajyaguru, Isabel Nájera, John A. Josey, Steven Swallow	46
9	Diversification of the Three-Component Coupling of 2-Aminoheterocycles, Aldehydes, and Isonitriles: Efficient Parallel Synthesis of a Diverse and Druglike Library of Imidazo- and Tetrahydroimidazo[1,2-a] Heterocycles 2007 ·Journal of Combinatorial Chemistry ·(unknown), Chang Rao, Josef R. Bencsik, John A. Josey	35
10	750 Preclinical characteristics of ITMN-B, an orally active inhibitor of the HCV NS3/4A protease nominated for preclinical development 2006 ·Journal of Hepatology ·Scott D. Seiwert, Steven W. Andrews, Hua Tan, (unknown), B J Marafino, Robert Rieger, (unknown), (unknown), Ying Jiang, Amy L. Kennedy, Jeanine Ballard, (unknown), Bryan A. Bernat, (unknown), Christine Lemieux, (unknown), John A. Josey, Lawrence M. Blatt	17
11	Efficient, Stereoselective Synthesis of Oxazolo[3,2‐a]pyrazin‐5‐ones: Novel Bicyclic Lactam Scaffolds from the Bicyclocondensation of 3‐Aza‐1,5‐ketoacids and Amino Alcohols. 2003 ·ChemInform ·Josef R. Bencsik, (unknown), Michael O’Sullivan, John A. Josey	2
12	Distinguishing diastereomeric organic compounds based on the concerted use of3J(C,H) and3J(N,H) values 1999 ·Magnetic Resonance in Chemistry ·Stefan Gröger, John A. Josey, Leszek Poppe	3
13	An efficient high-speed synthetic route to amino-substituted thiazolidinone libraries 1998 ·Tetrahedron Letters ·Mark Munson, Adam Cook, John A. Josey, Chang Rao	24
14	Impact of biophysical parameters on the biological assessment of peptide nucleic acids, antisense inhibitors of gene expression 1995 ·Drug Development Research ·Stewart A. Noble, Michele A. Bonham, John Bisi, David A. Bruckenstein, (unknown), Stephen C. Brown, Rodolfo Cadilla, Micheal D. Gaul, Jeffery C. Hanvey, C. Fred Hassman, John A. Josey, Michael J. Luzzio, (unknown), Adrian Pipe, Daniel J. Ricca, (unknown), Cynthia L. Stevenson, Stephen A. Thomson, Robert W. Wiethe, Lee E. Babiss	22
15	ChemInform Abstract: Fmoc‐Mediated Synthesis of Peptide Nucleic Acids. 1995 ·ChemInform ·Stephen A. Thomson, John A. Josey, Rodolfo Cadilla, Micheal D. Gaul, C. Fred Hassman, Michael J. Luzzio, Adrian Pipe, (unknown), Daniel J. Ricca, Robert W. Wiethe, Stewart A. Noble	3
16	General Method for the Synthesis of Phospholipid Derivatives of 1,2-O-Diacyl-sn-Glycerols 1994 ·The Journal of Organic Chemistry ·Stephen F. Martin, John A. Josey, (unknown), (unknown)	74
17	Antisense and Antigene Properties of Peptide Nucleic Acids 1992 ·Science ·Jeffery C. Hanvey, Nancy J. Peffer, John Bisi, Stephen A. Thomson, Rodolfo Cadilla, John A. Josey, Daniel J. Ricca, C. Fred Hassman, Michele A. Bonham, Karin G. Au, (unknown), David A. Bruckenstein, Ann L. Boyd, Stewart A. Noble, Lee E. Babiss	440
18	Diastereoselective [4+2] Cycloadditions of Acyl Nitroso Compounds 1992 ·Tetrahedron Letters ·Stephen F. Martin, Michael Hartmann, John A. Josey	56
19	A general protocol for the preparation of phospholipids via phosphite coupling 1988 ·Tetrahedron Letters ·Stephen F. Martin, John A. Josey	26
20	A new and efficient cyclization reaction to construct the bicyclomycin ring system: synthesis of N,N'-dimethyl-4-desmethylenebicyclomycin 1982 ·Journal of the American Chemical Society ·Robert M. Williams, Oren P. Anderson, Robert W. Armstrong, John A. Josey, Harold V. Meyers, (unknown)	19

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact